Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
P 1 (2)
P 2 (3)

Trial Status

Recruiting4
Withdrawn2

Clinical Trials (6)

Showing 6 of 6 trials
NCT07532824Phase 1Recruiting

Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS

NCT06284460Phase 1Withdrawn

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

NCT06778187Phase 2Recruiting

Oral-ATO for TP53-mutated Myeloid Malignancies

NCT04741945Phase 2Recruiting

Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS

NCT06111612Recruiting

Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement

NCT05829434Phase 2Withdrawn

Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS

Showing all 6 trials

Research Network

Activity Timeline